What is the market cap of Aminologics?

The market capitalisation of Aminologics was ₩90B at the close on Oct 30, 2026.

Who are the largest shareholders of Aminologics?

According to the latest official filings, the largest reported holders are Samo Pharmaceutical (39.20%, as of Oct 2, 2026); Orion Asset Management (4.40%, as of Oct 8, 2026); Oh Seong-seok (0.37%, as of Oct 2, 2026).

When is the next earnings report from Aminologics?

Korean companies rarely announce results dates in advance. Based on when Aminologics filed the same report in past years, its next 3q results is expected between Nov 8, 2026 and Nov 14, 2026.

KOSDAQ · 074430 · Biotech & Pharma · ₩074430

Aminologics아미노로직스

074430 · KOSDAQ · ₩074430 · 아미노로직스

₩1,009▲ ₩9 (0.90%)End-of-day · Oct 30, 2026 · End-of-day prices.

Trade

Price · 1Y +7.45%

Market cap: ₩90B
Enterprise value: ₩83B
P/E: 28.5×
P/B: 1.5×
Dividend yield: 0.0%
ROE: 5.4%
Net margin: 12.1%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−48.0% from the high

₩855Today: ₩980 – ₩1,015₩1,940

Returns

1W+2.0%
1M−3.4%
3M+0.7%
6M−27.3%
YTD−15.5%
1Y+7.5%

Volume today: 84,826; 1.1× the 20-day average
Traded today: ₩85M
Listed shares: 89,341,992
EPS (12 months): ₩35; Earnings yield 3.5%

Sell Buy

AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Nov 16Earnings Expected · 3Q results

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

X f WA TG r/in @

Signals

Normal

BuzzNormalBuzz 47 of 100 (50 is a normal day for this stock).
MomentumWeak-5.1% over the last month; the price is below its 20-day average.

Signals describe activity, not recommendations. Not financial advice.

Aminologics stock overview

Aminologics (아미노로직스, KRX: 074430) is listed on KOSDAQ, in the Biotech & Pharma sector. Aminologics is a South Korean company that sells active pharmaceutical ingredients (raw materials for drugs) and manufactures and sells amino acid derivative compounds. Its shares closed at ₩1,009 on Oct 30, 2026, up 0.90% on the day, giving it a market value of ₩90B.

Market cap: ₩90B
Sector: Biotech & Pharma
Latest price change: +0.90%
As of: Oct 30, 2026
Main business: Aminologics is a South Korean company that sells active pharmaceutical ingredients (raw materials for drugs) and manufactures and sells amino acid derivative compounds.

Quick answers about Aminologics

What does Aminologics do?: Aminologics is a South Korean company that sells active pharmaceutical ingredients (raw materials for drugs) and manufactures and sells amino acid derivative compounds. Its raw pharmaceutical ingredients are supplied to domestic pharmaceutical manufacturers for use in finished drugs and cosmetics, and its amino acid business serves industries such as pharmaceuticals, fine chemicals, food, and cosmetics.
What is the market cap of Aminologics?: The market capitalisation of Aminologics was ₩90B at the close on Oct 30, 2026.
Who are the largest shareholders of Aminologics?: According to the latest official filings, the largest reported holders are Samo Pharmaceutical (39.20%, as of Oct 2, 2026); Orion Asset Management (4.40%, as of Oct 8, 2026); Oh Seong-seok (0.37%, as of Oct 2, 2026).
When is the next earnings report from Aminologics?: Korean companies rarely announce results dates in advance. Based on when Aminologics filed the same report in past years, its next 3q results is expected between Nov 8, 2026 and Nov 14, 2026.

Company profile

Aminologics is a South Korean company that sells active pharmaceutical ingredients (raw materials for drugs) and manufactures and sells amino acid derivative compounds. Its raw pharmaceutical ingredients are supplied to domestic pharmaceutical manufacturers for use in finished drugs and cosmetics, and its amino acid business serves industries such as pharmaceuticals, fine chemicals, food, and cosmetics.

Written by AI from the company's latest annual report.

Korean name: 아미노로직스
Sector: Biotech & Pharma
Themes: Biotech (new drugs)
CEO: 오장석,오성석
Founded: Sep 1997
Listed: Jun 2004
Listed shares: 89,341,992
Fiscal year ends: Month 12
Website: www.aminologics.co.kr

Similar companies

Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
Celltrion068270 · ₩44T₩191,600+1.22%
Alteogen196170 · ₩15T₩211,500−3.86%
SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
Yuhan000100 · ₩5.5T₩75,100+0.54%
HLB028300 · ₩5.3T₩40,000+0.76%
Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%

Recent filings

See all

Titles in Korean until English translations are added.

Key numbers

Volume: 84,826
Traded value: ₩85M
Day range: ₩980 – ₩1,015
Revenue (TTM): ₩26B
Operating margin: 20.9%
Net margin: 12.1%
ROE: 5.4%
Revenue growth (last year): +31.1%
Liabilities to equity: 54%
Foreign ownership: 2.66%
Short balance: 0.19%

Trailing 12 months from filed financial statements, as of H1 2026.

Who owns Aminologics?

Samo Pharmaceutical삼오제약10%이상주주5% reportInsider report39.20%39M sharesas of Oct 2, 2026
Orion Asset Management오라이언자산운용5% report4.40%4.1M sharesas of Oct 8, 2026
Oh Seong-seok오성석CEOInsider report0.37%333.6K sharesas of Oct 2, 2026
Oh Jang-seok오장석CEOInsider report0.37%333.6K sharesas of Oct 2, 2026
EMERGING MARKETS CORE EQUITY 2 PORTFOLIODFA INVESTMENT DIMENSIONS GROUP INCN-PORT0.13%115.2K shares≈ $80.3Kas of Jul 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETFDimensional ETF TrustN-PORT0.01%9.6K shares≈ $6.8Kas of Jul 31, 2026

From official filings only: 5% reports and executives' and major shareholders' reports (Korea), and US funds' Form N-PORT and US managers' Form 13F (ADRs) reports. Each holder shows its latest report and the date it was as of; the same holder in two reports is shown once.

Also known as: Aminologics / 아미노로직스 / 074430 / KRX:074430

Source: KRX statistical information